edge by both clinicians and laboratory sta¡ has been demonstrated. 3 Finally, it provides a framework of haemolysis grades to which comments regarding other analytes a¡ected by haemolysis (e.g. AST) can be attached. This system has been successfully implemented --with positive feedback from clinicians similar to that noted by Dimeski--and provides another option for laboratories dealing with this vexing problem.
Sorting the wheat from the chaff in macroprolactinaemia assessment
We read with great interest the review 'Macroprolactin; high molecular mass forms of circulating prolactin' by Fahie-Wilson et al. and the papers by Gibney et al. published by two of the leading clinical endocrinology journals that reached two completely di¡erent conclusions. 1--3 Gibney et al. concluded that macroprolactinaemia is a common cause of elevated prolactin (PRL) levels, which often induce inappropriate investigation and treatment. According to the authors, the routine screening for macroprolactinaemic samples should be extended to all the hyperprolactinaemic patients. The topic surely interests both clinicians and laboratorians and the paper was the second most read JCEM paper in July 2005 4 --and has been appreciated in August also. 5 However, the much more balanced review by Fahie-Wilson et al. concluded that the screening for macroprolactin is probably mandatory only when the laboratory uses assays that react highly with macroprolactin
As a multidisciplinary group working in the ¢eld ofendocrinological diagnosis, we think that it does not appear reasonable to apply the same rules to assays with radically di¡erent performance. Actually, it has been known for many years that macroprolactin reacts variably both in radioimmunoassays and automated assays for serum PRL. The results by Gibney et al. are consistent with previous reports showing that some commercial assays, widely used worldwide, react with macroprolactin in about a quarter of the samples. On the other hand, Fahie-Wilson's review reminds us that other assays react in as few as about 1% of the samples; a 25-fold di¡erence. 6, 7 Considering the highly di¡erent cross-reaction with macroprolactin of the di¡erent commercial assays, is it wise to advocate a routine screening for macroprolactin for all the assays for prolactin? Is it not better to recommend that an increased PRL concentration is con¢rmed after 30--60 min of saline infusion and eventually after precipitation with polyethyleneglycol (PEG)? Moreover, are reports of prolactin without the indication of the used assay useful to clinicians?
Endocrinology and Laboratory Medicine professional organizations and scienti¢c societies should recommend that clinical laboratories indicate the assay used in the reports of all the endocrinological assays and especially of prolactin. This could allow the clinicians to establish the reliability of the report.
In conclusion, in the assessment of the cost-e¡ectiveness of routine screening for macroprolactin, we should pay attention to the analytical assay used, sorting the wheat from the cha¡. This is a further evidence for the need of a better 'knowledge transfer' between clinicians and laboratorians and vice versa. Letters edge by both clinicians and laboratory sta¡ has been demonstrated. 3 Finally, it provides a framework of haemolysis grades to which comments regarding other analytes a¡ected by haemolysis (e.g. AST) can be attached. This system has been successfully implemented --with positive feedback from clinicians similar to that noted by Dimeski--and provides another option for laboratories dealing with this vexing problem.
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